{"title":"客座编辑对“加拿大人需要改善罕见病药物的获取，而不是更多的拒绝”的回应。","authors":"Joel Lexchin","doi":"10.12927/hcpap.2023.27198","DOIUrl":null,"url":null,"abstract":"<p><p>Rawson and Adams (2023) are certainly entitled to express their views about the lead and response articles by Sirrs et al. (2023a; 2023b). Their entitlement comes with a responsibility to accurately and comprehensively state their conflicts of interest (COI) so that readers can assess whether their arguments may be influenced by other interests.</p>","PeriodicalId":101342,"journal":{"name":"HealthcarePapers","volume":"21 3","pages":"70-71"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Guest Editor's Response to \\\"Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial\\\".\",\"authors\":\"Joel Lexchin\",\"doi\":\"10.12927/hcpap.2023.27198\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Rawson and Adams (2023) are certainly entitled to express their views about the lead and response articles by Sirrs et al. (2023a; 2023b). Their entitlement comes with a responsibility to accurately and comprehensively state their conflicts of interest (COI) so that readers can assess whether their arguments may be influenced by other interests.</p>\",\"PeriodicalId\":101342,\"journal\":{\"name\":\"HealthcarePapers\",\"volume\":\"21 3\",\"pages\":\"70-71\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HealthcarePapers\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12927/hcpap.2023.27198\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HealthcarePapers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12927/hcpap.2023.27198","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Guest Editor's Response to "Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial".
Rawson and Adams (2023) are certainly entitled to express their views about the lead and response articles by Sirrs et al. (2023a; 2023b). Their entitlement comes with a responsibility to accurately and comprehensively state their conflicts of interest (COI) so that readers can assess whether their arguments may be influenced by other interests.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
